VivoSeq
Other

Plasma Cell Disorders

0

Pipeline Programs↗

4

Active Trials↗

0

Companies Involved↗

Plasma Cell Disorders is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Not yet recruiting2 · 40%
Recruiting2 · 40%
Completed1 · 20%

Clinical Trials

Trial Activity

Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders
Not yet recruiting·—·Phase 1·NCT07365059·18 enrolled
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Recruiting·UUniversity of Arkansas·Phase 1·NCT06313502·18 enrolled
High Dose Ascorbic Acid for Plasma Cell Disorders
Completed·—·Phase 1·NCT03602235·6 enrolled
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Recruiting·UUniversity of Maryland, Baltimore·Phase 1/2·NCT07075510·30 enrolled
A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET/CT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders
Not yet recruiting·PPeking University First Hospital·Phase 1·NCT07660939·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)